Getinge Announces New BioProcess Control System
Getinge is launching Livit Flex, a bioprocess control system designed to help pharmaceutical and biotech products get to market faster.
Getinge, a Swedish medical technology company, announced the launch of the LivitFlex bioprocess control system. The system is designed to help pharmaceuticals and biotechnology products reach market faster.
According to a Dec. 15, 2022 press release, the LivitFlex speeds up development through system flexibility, smart sensor technology, and easy-to-use software functionalities. Additionally, by accessing and controlling multiple controllers from a PC or tablet in a laboratory, users can set up parallel experiments and monitor all data from one central location.
“Combining the flexibility of the Livit Flex controller, the intuitive Livit software, and Getinge bioreactors enables acceleration of R&D processes to make sure that pharmaceuticals and biotech products will ultimately end up faster where they are most needed – with the patients,” said Matthijs Niemeijer, head, Product Management Bioreactor Systems, Getinge, in the release.
Source: Getinge
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
